Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Ambulatory and Non-Ambulatory Participants With Spinal Muscular Atrophy With Open-Label Extension

NCT05337553 is registered in ClinicalTrials.gov with Biohaven Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05337553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05337553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Ambulatory and Non-Ambulatory Participants With Spinal Muscular Atrophy With Open-Label Extension
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 6, 2022
Completion date
December 31, 2027
Enrollment
269 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

neuromuscular diseases, sma, spinal muscular atrophy